Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
Participant gender:
Summary
The study is a randomized, parallel, 4-dose design in subjects with mild-to-moderate
Alzheimer's Disease. Subjects will be randomized to one of 4 doses of T3D-959. Subjects will
be evaluated for changes from baseline in cerebral metabolic rate of glucose (FDG-PET
imaging), functional connectivity of the hippocampus (BOLD-fMRI), and cognitive function
(ADAS-Cog11 and DSST) as well as assessed for safety and tolerability to T3D-959.
An expanded access extension is planed to provide access to study medication to subjects who
have completed the main study and requested continued use.